UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049690
Receipt number R000056596
Scientific Title Clinical Study on the Therapeutic Effects of Anti-Vascular Endothelial Growth Factor Therapy and Combined Steroid Therapy in Macular Edema Associated with Retinal Vein Occlusion in Relation to Cytokines
Date of disclosure of the study information 2023/02/21
Last modified on 2023/12/13 09:15:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical Study on the Therapeutic Effects of Anti-Vascular Endothelial Growth Factor Therapy and Combined Steroid Therapy in Macular Edema Associated with Retinal Vein Occlusion in Relation to Cytokines

Acronym

Therapeutic Effects of Anti-VEGF Therapy Versus Steroid Combination in RVO

Scientific Title

Clinical Study on the Therapeutic Effects of Anti-Vascular Endothelial Growth Factor Therapy and Combined Steroid Therapy in Macular Edema Associated with Retinal Vein Occlusion in Relation to Cytokines

Scientific Title:Acronym

Therapeutic Effects of Anti-VEGF Therapy Versus Steroid Combination in RVO

Region

Japan


Condition

Condition

Patients with macular edema associated with retinal vein occlusion

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the relationship between treatment efficacy and ocular cytokine kinetics in macular edema associated with RVO

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Anti-VEGF treatment efficacy and cytokine levels

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

(1) Patients with macular edema associated with retinal vein occlusion
(2) Patients with visual acuity of 0.8 or less and central retinal thickness of 300um or more
(3) Patients scheduled to receive anti-VGEF medication and expected to continue for at least 12 months
(4) Patients who have not been treated with laser, surgery, or injections at other hospitals
(5) Patients who have been informed of the purpose and content of this study and have given their free and voluntary consent
(6) Patients who are able to visit the hospital and undergo examinations during the observation period

Key exclusion criteria

(1) Patients undergoing other ocular surgery or intravitreal injection of various drugs
(2) Patients with the following diseases
Patients with active uveitis
Patients with iris neovascularization
Patients with poorly controlled glaucoma
Progressive diabetic retinopathy
(3) Other patients deemed inappropriate for inclusion in the study by the investigator
(4) Patients who refuse to cooperate in this study

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Hidetaka
Middle name
Last name Noma

Organization

Tokyo Medical University Hachioji Medical Center

Division name

Department of Ophthalmology

Zip code

193-0998

Address

1163 Tate-machi, Hachioji, Tokyo

TEL

+81426655611

Email

nomahide1122@gmail.com


Public contact

Name of contact person

1st name Hidetaka
Middle name
Last name Noma

Organization

Tokyo Medical University Hachioji Medical Center

Division name

Department of Ophthalmology

Zip code

193-0998

Address

1163 Tate-machi, Hachioji, Tokyo

TEL

+81426655611

Homepage URL


Email

nomahide1122@gmail.com


Sponsor or person

Institute

Tokyo Medical University

Institute

Department

Personal name



Funding Source

Organization

Tokyo Medical University

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board in Tokyo Medical University

Address

6-7-1 Nishi-Shinjuku, Shinjuku, Tokyo

Tel

0333426111

Email

tokyo-med@esct.bvits.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 02 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 02 Month 21 Day

Date of IRB

2022 Year 11 Month 18 Day

Anticipated trial start date

2022 Year 11 Month 30 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Treatment naive macular edema in RVO
To study the eyes in which anti-VEGF drug therapy or steroid combination therapy was administered.

Collection of visual acuity, retinal thickness, flare values, blood flow, retinal sensitivity and vascular density

Collection of the duration and frequency of anti-VEGF therapy, and whether and how often steroids are used


Management information

Registered date

2022 Year 12 Month 05 Day

Last modified on

2023 Year 12 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056596


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name